Welcome to our dedicated page for Azitra news (Ticker: AZTR), a resource for investors and traders seeking the latest updates and insights on Azitra stock.
Azitra Inc (AZTR) is a clinical-stage biopharmaceutical leader advancing precision dermatology through engineered microbial therapies. This page serves as the definitive source for verified updates on the company's scientific progress and corporate developments.
Investors and industry observers will find timely information on clinical trial milestones, regulatory filings, and research collaborations. Our curated news collection covers essential updates including therapeutic pipeline advancements, intellectual property developments, and strategic partnership announcements.
All content undergoes rigorous verification to ensure accuracy and relevance. The news archive maintains focus on material developments in Azitra's core areas: live biotherapeutic products, genetic engineering innovations, and dermatological treatment solutions. Regular updates provide insight into the company's progress addressing conditions like Netherton syndrome and EGFR inhibitor-associated rashes.
Bookmark this page for efficient tracking of Azitra's advancements in microbial therapeutics and precision dermatology research. For comprehensive understanding of the company's scientific approach, review our detailed company profile alongside these verified updates.
Azitra (NYSE American: AZTR) has entered into a share purchase agreement with Alumni Capital LP for up to $20 million in funding over a 20-month period. The agreement allows Azitra to sell common stock and warrants to Alumni Capital at market-based prices, with Azitra maintaining full control over the timing and amount of sales.
The funding will support Azitra's clinical pipeline development of live biotherapeutic precision products for rare and severe dermatologic conditions, specifically focusing on Netherton Syndrome and EGFRi associated rash, which affects approximately 150,000 people in the U.S. The company aims to minimize dilution while maintaining shareholder value through this flexible funding arrangement.
Azitra (NYSE American: AZTR), a clinical-stage biopharmaceutical company specializing in precision dermatology, has announced its participation in the upcoming Microbiome Times Partnering Forum in Brussels, Belgium, scheduled for March 18-19, 2025.
Chief Operating Officer Travis Whitfill, Ph.D., MPH, will lead the company's presentation at the forum. The event will provide an opportunity for Azitra's management team to conduct one-on-one meetings with registered investors and potential partners. During these sessions, they will showcase their business and clinical development strategy, recent corporate achievements, and upcoming milestones.
Azitra (NYSE: AZTR) reported its full year 2024 financial results and business updates. The company initiated a Phase 1b trial for ATR-12 in Netherton syndrome patients, with initial safety data expected in H1 2025 and topline data by year-end 2025. The FDA cleared a Phase 1/2 study of ATR-04 for EGFRi-associated dermal toxicity and granted it Fast Track designation.
Financial highlights include: service revenue of $0.8K (down from $0.7M in 2023), R&D expenses of $4.7M (up from $3.6M), G&A expenses of $6.3M (up from $4.5M), and a net loss of $9.0M (improved from $11.3M in 2023). Cash position stood at $4.6M as of December 31, 2024, with additional $2.2M raised in early 2025.
The company completed public offerings totaling $15M and strengthened its IP portfolio. ATR-04 targets a market opportunity exceeding $1B, affecting approximately 150,000 US patients annually.
Azitra (NYSE American: AZTR) has announced a registered direct offering of 3,339,300 shares of common stock priced at $0.2785 per share, expected to raise approximately $930,000 in gross proceeds. The offering, scheduled to close on February 5, 2025, is being conducted with institutional investors through a securities purchase agreement.
The company plans to use the net proceeds for working capital and general corporate purposes. Maxim Group is serving as the sole placement agent for the offering, which is being made under an effective shelf registration statement on Form S-3 filed with the SEC on July 1, 2024, and declared effective on July 8, 2024.
Azitra (NYSE American: AZTR), a clinical stage biopharmaceutical company specializing in precision dermatology, has announced its participation in the upcoming BIO CEO & Investor Conference. The event will take place on February 10-11, 2025, in New York City.
The company's presentation is scheduled for February 10, 2025, at 3:45 p.m. ET in the Royale Room at The New York Marriott Marquis. Travis Whitfill, Chief Operating Officer, will lead the presentation.
During the conference, Azitra's management team will engage in one-on-one meetings with registered investors and potential partners. These meetings will focus on discussing the company's business and clinical development strategy, recent corporate achievements, and upcoming milestones.
Azitra (NYSE American: AZTR), a clinical stage biopharmaceutical company specializing in precision dermatology, has announced its participation in The Microcap Conference 2025. The presentation is scheduled for January 29, 2025, at 11:00 a.m. ET at the Borgata Hotel Casino & Spa in Atlantic City, NJ.
Chief Executive Officer Francisco Salva will lead the presentation in Studio C. During the conference, which runs from January 28-30, 2025, the company's management team will engage in one-on-one meetings with registered investors and potential partners. These meetings will focus on discussing Azitra's business and clinical development strategy, recent corporate achievements, and upcoming milestones.
Azitra (NYSE American: AZTR), a clinical-stage biopharmaceutical company specializing in precision dermatology, has announced the pricing of its public offering of 4,857,780 shares of common stock at $0.30 per share. The offering is expected to generate gross proceeds of approximately $1.5 million before deducting placement agent fees and other expenses.
The offering is scheduled to close on January 16, 2025, subject to customary conditions. The company plans to use the net proceeds for working capital and general corporate purposes. Maxim Group is serving as the sole placement agent for this offering, which is being conducted under an effective shelf registration statement previously filed with the SEC.
Azitra (NYSE American: AZTR), a clinical-stage biopharmaceutical company specializing in precision dermatology, has announced the commencement of a public offering of common stock and pre-funded warrants. Maxim Group will serve as the sole placement agent for the offering.
The company plans to utilize the net proceeds for working capital and general corporate purposes. The offering is being conducted through an effective shelf registration statement on Form S-3 filed with the SEC on July 1, 2024, and declared effective on July 8, 2024. The completion, size, and terms of the offering are subject to market conditions and cannot be guaranteed.
Azitra (NYSE American: AZTR), a clinical stage biopharmaceutical company specializing in precision dermatology, has announced its participation in Biotech Showcase 2025. The event will take place from January 13-15, 2025 in San Francisco, with Azitra's presentation scheduled for January 13 at 3:00 p.m. PT at the Hilton San Francisco Union Square.
Chief Operating Officer Travis Whitfill will lead the presentation, and the company's management team will conduct one-on-one meetings with registered investors and potential partners. These meetings will focus on discussing Azitra's business strategy, clinical development plans, recent achievements, and future milestones.
The Biotech Showcase, organized by Demy-Colton and EBD Group, serves as a leading investor conference for private and micro-mid-cap biotechnology companies to present their innovations and connect with investors.
Azitra (AZTR) reported Q3 2024 financial results and business updates. Key highlights include completing a $10 million follow-on offering, dosing the first Netherton syndrome patient with ATR-12, and receiving FDA Fast Track designation for ATR-04. Financial results show zero service revenue compared to $310,700 in Q3 2023, R&D expenses of $1.0 million (up from $0.5 million), and G&A expenses of $1.9 million. The company reported a net loss of $1.0 million and held cash and equivalents of $7.3 million as of September 30, 2024. Upcoming milestones include initial safety data and first patient dosing for key trials in Q1 2025.
